Retinal Antigens Are Recognized by Antibodies Present in Sera of Patients with Multiple Sclerosis

Gorczyca, Wojciech; Ejma, Maria; Witkowska, Danuta; Misiuk-Hojło, Marta; Kuropatwa, Marianna; Mulak, Małgorzata; Szymaniec, S

doi:10.1159/000076892

Cited by 31 publications

(16 citation statements)

References 15 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies against NNE have also been implicated as a cause of autoimmune retinopathy (8)(9)(10). We, and others have reported the presence of anti-NNE antibodies in association with retinopathy in MS patients (11,12). Furthermore, we have reported an increased prevalence of enolase autoantibodies in MS patients compared to healthy controls (13).…”

Section: Introductionsupporting

confidence: 59%

“…It is well known that MS is associated with intermediate uveitis (26)(27)(28) and arrestin can be used to induce experimental autoimmune uveoretinitis (EAU) (29)(30)(31). Autoantibodies to both brain and retina arrestin have been reported in MS patients (11,32,33), although the T-cell proliferative response to this antigen has not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enolase and Arrestin are Novel Nonmyelin Autoantigens in Multiple Sclerosis

et al. 2007

View full text Add to dashboard Cite

Introduction-Although myelin autoimmunity is known to be a major factor in the pathogenesis of multiple sclerosis (MS), the role of nonmyelin antigens is less clear. Given the complexity of this disease, it is possible that autoimmunity against nonmyelin antigens also has a pathogenic role. Autoantibodies against enolase and arrestin have previously been reported in MS patients. The Tcell response to these antigens, however, has not been established.

show abstract

Section: Introductionsupporting

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Enolase and Arrestin are Novel Nonmyelin Autoantigens in Multiple Sclerosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The presence of autoantibodies to a 46-kD antigen identified as ·-enolase was reported in studies on CAR and other autoimmunity-based diseases [4,[25][26][27]. In sera of some cancer patients, neuronal Á-enolase was detected [28] and it was also possible that anti-p46 antibodies were directed against this protein.…”

Section: Discussionmentioning

confidence: 82%

Serum Antibodies to Retinal Antigens in Lung Cancer and Sarcoidosis

et al. 2004

View full text Add to dashboard Cite

Objective: Autoantibodies to various neuronal proteins frequently accompany lung cancer and their appearance may precede cancer symptoms. In this study we examined which retinal antigens (RAs) are recognized by sera of patients with lung cancer and whether the occurrence of serum antibodies to particular RAs is characteristic for cancer in comparison with a noncancer lung disease. Methods: Sera of 72 patients with non-small-cell lung cancer (NSCLC), 29 with small-cell lung cancer (SCLC), 27 with sarcoidosis (S), and sera of 32 healthy donors were examined in immunoblotting using retinal extracts and purified RAs as antigens. Results: 69.0% of SCLC, 45.8% of NSCLC, and 44.4% of S sera displayed anti-RAs reactivity. Significantly less (p < 0.05; χ² test) percent of healthy control sera reacted with RAs. Lung cancer sera recognized mainly 46-, 56-, and 36-kD and to a smaller extent also 96-, 72-, 43-, and 26-kD proteins. Most of them were recognized with about 2-fold lower frequencies by S and control sera. Only lung cancer sera contained very high-titer antibodies to 46- and 26-kD RAs, identified as α-enolase and recoverin, respectively. Conclusion: Antibodies to RAs occur more frequently and in higher titers in lung cancer (especially SCLC) than in sarcoidosis or control sera. Although antibodies to retinal α-enolase, recoverin and other RAs are present mainly or exclusively in lung cancer sera, none of them seems to be a specific marker of a particular disease.

show abstract

“…We recently reported a case of retinal degeneration without clinical inflammation in a patient with MS who was found to have strong antibody reactivity against α-enolase [35]. Following this, another study found that antibodies against a 46 kDa protein (confirmed to be α-enolase) were present in 17 out of 28 (61%) of MS patients, and that some of the patients with high antibody titres had reduced electroretinograms (ERGs) and/or visual impairment [36]. This study, however, did not contain a detailed analysis of all ERG parameters with ISCEV standards.…”

Section: Introductionmentioning

confidence: 95%

Enolase autoantibodies and retinal function in multiple sclerosis patients

Forooghian

Adamus

Sproule

et al. 2007

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Factors affecting the retina other than alpha-enolase antibodies may account for the delayed rod-cone b-wave implicit times observed in MS patients in this study. Anti-enolase antibodies are likely an epiphenomenon of autoimmune disease, and are not causing retinopathy in MS patients with normal visual acuity. However, the possibility of rare cases of patients with pathogenic alpha-enolase autoantibodies can not be excluded. The pathogenic contribution of these antibodies in MS patients with visual impairment deserves further investigation.

show abstract

Retinal Antigens Are Recognized by Antibodies Present in Sera of Patients with Multiple Sclerosis

Cited by 31 publications

References 15 publications

Enolase and Arrestin are Novel Nonmyelin Autoantigens in Multiple Sclerosis

Enolase and Arrestin are Novel Nonmyelin Autoantigens in Multiple Sclerosis

Serum Antibodies to Retinal Antigens in Lung Cancer and Sarcoidosis

Enolase autoantibodies and retinal function in multiple sclerosis patients

Contact Info

Product

Resources

About